Source: Annual Congress 2010 - Biomarkers for lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Mundt, R. Dück, S. Gütz (Leipzig, Germany). Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy. Eur Respir J 2010; 36: Suppl. 54, 3237

Member's Comments

No comment yet.

Related content which might interest you: The prognostic value of the expression of GST-π in response to chemotherapy in cytological and pathological specimens of patients with lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 The role of P53 tumor suppressor gene mutations in early diagnosis of lung cancer among patients with solitary pulmonary nodule Source: Annual Congress 2009 - Pathogenesis of lung cancer Year: 2009 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients Source: Eur Respir J 2012; 40: 267-269 Year: 2012 Correlation of p53, EGFR and HER2 expression in the diagnostic biopsies and the corresponding resected tumours in NSCLC Source: Eur Respir J 2003; 22: Suppl. 45, 198s Year: 2003 Correlation of P53 and CerbB-2 expression in the diagnostic biopsies and the corresponding resected tumors in non small cell lung caner Source: Eur Respir J 2004; 24: Suppl. 48, 43s Year: 2004 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Loss of heterozygosity off the P16, P53 and APC gene in oral cavity exfoliate cytologic material among lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 457s Year: 2005 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Model for predicting EGFR mutation status in lung cancer Source: Breathe, 15 (4) 340; 10.1183/20734735.0250-2019 Year: 2019 Dynamic monitoring of EGFR mutations in circulating tumor DNA for early detection of drug resistance in NSCLC patients on EGFR-TKI therapy Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer Source: Eur Respir J 2011; 38: 903-910 Year: 2011 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1551 Year: 2012 Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 1550-1551 Year: 2012 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006